Our Pricing

Weight Loss Prescription Discount Code UK: Save 10% Today

Published on: June 03, 2026

Searching for a weight loss prescription discount code UK offer that's genuine and transparent? At Cured Pharmacy, use code WEIGHTLOSSNEW to save 10% on your first prescription weight loss treatment. Our UK-registered clinical team provides free consultations, upfront pricing, and discreet delivery of MHRA-licensed medications including Mounjaro, Wegovy, Saxenda, and Orlistat.

How Prescription Weight Loss Medications Work

Prescription weight loss treatments available through UK pharmacies fall into three main categories: GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and lipase inhibitors. Each works through distinct mechanisms to support weight management when combined with lifestyle modifications [1].

GLP-1 medications like semaglutide and liraglutide mimic natural gut hormones that regulate appetite and blood sugar. They slow gastric emptying and enhance satiety signals to the brain, helping patients feel fuller for longer periods [2]. Clinical trials demonstrate these medications can support average weight reductions of 10-15% over 68 weeks when used alongside dietary changes [2].

Tirzepatide represents a newer dual-action approach, activating both GIP and GLP-1 receptors simultaneously. This dual mechanism has shown superior results in clinical trials, with patients achieving up to 22.5% average body weight reduction over 72 weeks in the SURPASS-3 study [3]. The MHRA licensed tirzepatide for weight management in the UK in 2023, offering patients an additional evidence-based option.

Understanding Your Treatment Options

Your UK prescriber will assess several factors when recommending a weight loss medication: your current BMI, medical history, previous weight loss attempts, and any contraindications. Prescription treatments are typically considered for adults with a BMI of 30 or above, or 27 and above with weight-related health conditions [4].

All prescription weight loss medications require ongoing clinical monitoring and work best as part of a comprehensive programme including dietary modifications and increased physical activity. Your prescriber will discuss realistic expectations, potential side effects, and the importance of gradual dose escalation to minimise gastrointestinal symptoms.

Comparing Injectable Weight Loss Treatments

Injectable GLP-1 and dual GIP/GLP-1 treatments have transformed prescription weight management in the UK. Each medication offers distinct advantages depending on your individual circumstances and treatment goals.

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management. Clinical trials show it produces greater average weight loss compared to single-pathway alternatives, with patients in the SURMOUNT-1 trial achieving 15-22.5% body weight reduction depending on dose [3]. The once-weekly injection uses a convenient KwikPen device and requires gradual dose escalation over several months.

Wegovy contains semaglutide, a well-established GLP-1 receptor agonist with extensive clinical data. The STEP trial programme demonstrated average weight loss of 14.9% over 68 weeks, with significant improvements in cardiovascular risk markers [2]. Wegovy is administered once weekly and has been available in the UK since 2023, offering a proven alternative for patients who meet prescribing criteria.

Saxenda uses liraglutide, an earlier-generation GLP-1 medication requiring daily injection rather than weekly administration. Whilst clinical data shows smaller average weight reductions compared to newer alternatives (typically 5-10% over 56 weeks), Saxenda remains a valuable option for certain patients and offers flexible dosing [5].

Which Injectable Treatment Suits You?

Your UK prescriber will consider multiple factors when recommending an injectable treatment: your weight loss goals, tolerance for side effects, injection frequency preference, and budget. Newer dual-action medications typically show greater efficacy in clinical trials but come at higher cost, whilst established treatments offer proven safety profiles with longer real-world usage data.

All injectable weight loss medications share similar potential side effects, predominantly gastrointestinal symptoms like nausea, diarrhoea, and constipation. These typically diminish over time and can be minimised through gradual dose escalation and dietary adjustments. Your prescriber will monitor your progress and adjust treatment as needed.

Oral Weight Loss Medications: Orlistat and Mysimba

For patients who prefer oral medications or have contraindications to injectable treatments, the UK market offers two licensed alternatives: orlistat and Mysimba. Both work through entirely different mechanisms compared to GLP-1 medications.

Orlistat (available as prescription-strength 120mg capsules under brand names Xenical and generic formulations, or lower-dose 60mg versions like Alli and Orlos) works by blocking approximately 30% of dietary fat absorption in the intestines [6]. This mechanism means undigested fat passes through the digestive system, which can cause gastrointestinal side effects if patients consume high-fat meals. Clinical trials show orlistat supports average weight loss of 5-10% when combined with a reduced-calorie, lower-fat diet [6].

Mysimba combines naltrexone and bupropion, two medications that work on the central nervous system to reduce appetite and food cravings. Clinical data demonstrates average weight loss of 5-9% over 56 weeks in patients who complete the treatment programme [7]. Mysimba requires careful dose titration and is not suitable for patients with uncontrolled hypertension, seizure disorders, or those taking certain other medications.

Choosing Between Injectable and Oral Treatments

Injectable GLP-1 medications generally produce greater average weight loss in clinical trials compared to oral alternatives, but oral treatments offer advantages for certain patients. Orlistat works locally in the gut without systemic absorption, making it suitable for patients with conditions that contraindicate GLP-1 medications. Mysimba provides an alternative mechanism for patients who cannot tolerate or do not respond adequately to other options.

Your UK prescriber will discuss the evidence base for each treatment, realistic expectations, and which option aligns best with your medical history and lifestyle. All prescription weight loss medications require commitment to dietary changes and increased physical activity to achieve optimal results.

How to Use Your Weight Loss Discount Code

Accessing prescription weight loss treatment through Cured Pharmacy is straightforward and fully compliant with UK regulations. Every prescription medication requires clinical assessment by our UK-registered prescribers before dispensing.

Start by selecting your preferred treatment from our weight loss category and clicking 'Start Assessment'. You'll complete a comprehensive medical questionnaire covering your health history, current medications, weight loss goals, and any relevant conditions. This typically takes under three minutes and provides our clinical team with essential information to assess suitability.

A UK-registered prescriber reviews your assessment, usually within 24 hours on working days. If approved, they'll issue a prescription and our pharmacy team dispenses your medication for discreet delivery. Your discount code WEIGHTLOSSNEW applies automatically at checkout, reducing your first order by 10%. All pricing is transparent and shown upfront before you begin the consultation process.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all dispensing from our UK-registered pharmacy (GPhC 9012511). We supply only genuine MHRA-licensed medications sourced through legitimate UK channels, never grey-market imports or unlicensed alternatives.

What to Expect During Weight Loss Treatment

Starting prescription weight loss medication involves a gradual process designed to minimise side effects and optimise results. Understanding what to expect helps you prepare for successful treatment.

Most injectable treatments begin with a low starter dose that increases incrementally over 8-20 weeks depending on the medication. This gradual escalation allows your body to adjust and significantly reduces the likelihood of nausea and other gastrointestinal symptoms. Your prescriber will provide a specific dosing schedule tailored to your chosen treatment [1][3].

Common side effects during the initial weeks include mild to moderate nausea, occasional diarrhoea or constipation, and reduced appetite. These typically diminish as your body adapts to the medication. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated can help manage symptoms. Severe or persistent side effects should be reported to your prescriber immediately.

Weight loss typically becomes noticeable after 4-8 weeks of treatment, with continued gradual reduction over subsequent months. Clinical trials show most patients achieve their maximum weight loss between 60-72 weeks of continuous treatment [2][3]. Regular monitoring through follow-up consultations ensures your treatment remains safe and effective throughout your weight loss journey.

Maximising Treatment Success

Prescription weight loss medications are most effective when combined with sustainable lifestyle changes. Your prescriber will recommend dietary modifications appropriate to your medication—for example, patients taking orlistat must follow a lower-fat diet to minimise side effects, whilst those on GLP-1 medications benefit from smaller, more frequent meals to accommodate reduced appetite.

Regular physical activity enhances weight loss outcomes and helps maintain results long-term. NICE guidelines recommend gradually increasing activity levels to at least 150 minutes of moderate-intensity exercise weekly [4]. Setting realistic goals, tracking progress, and addressing emotional eating patterns all contribute to successful weight management beyond medication alone.

Safety Considerations and Contraindications

Prescription weight loss medications are powerful tools that require careful patient selection and ongoing monitoring. UK prescribers follow MHRA guidance and NICE recommendations when assessing suitability.

GLP-1 and dual GIP/GLP-1 medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. They should be used cautiously in patients with history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy [1][2]. Pregnancy and breastfeeding are absolute contraindications for all prescription weight loss treatments.

Orlistat is generally well-tolerated but can interfere with absorption of fat-soluble vitamins and certain medications. Patients taking levothyroxine, warfarin, or anticonvulsants require careful monitoring and dose timing adjustments [6]. Mysimba cannot be used alongside MAO inhibitors, in patients with seizure disorders or eating disorders, or in those with uncontrolled hypertension [7].

Your UK prescriber reviews your complete medical history, current medications, and any allergies before approving treatment. They'll discuss potential drug interactions, warning signs requiring immediate medical attention, and the importance of regular follow-up. Never purchase prescription weight loss medications from unregistered sources or without proper clinical assessment—this poses serious health risks and is illegal in the UK.

Scientific References

1. Frias, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
7. Greenway, F. L., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.